ZJYLNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends September 30

Jin Medical International Ltd.

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Feb 10, 2026

$2.11+0.03 (+1.44%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 10.5
Dividend yield: –

Jin Medical International Ltd. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenue	21	24	20	19	21
Cost of Revenue	15	14	13	13	14
Gross Profit	6.04	9.50	6.78	6.20	6.36
Research & Development	1.56	1.50	1.54	1.89	1.57
General & Administrative	2.53	3.26	1.92	1.77	1.67
Operating Expenses	5.44	5.86	3.92	4.07	3.73
Operating Income	0.61	3.64	2.87	2.13	2.63
Interest & Investment Income	0.79	0.47	0.18	0.18	0.06
Other Non-Operating Income	0.99	0.54	0.35	0.61	–
Gain (Loss) on Investments	0.05	0.05	–	–	–
Gain (Loss) on Sale of Assets	-0.04	0.00	0.01	–	-0.01
Pretax Income	1.60	4.18	3.22	2.74	2.88
Income Tax Expense	0.21	0.76	0.34	0.04	0.25
Net Income incl. Noncontrolling Interests	1.38	3.42	2.88	2.71	–
Minority Interest in Earnings	0.19	-0.26	–	–	–
Net Income	1.19	3.68	2.88	2.71	2.63
EPS (Basic)(per share)	0.20	0.40	0.40	0.40	0.40
EPS (Diluted)(per share)	0.20	0.40	0.40	0.40	0.40
Shares Outstanding (Basic, Weighted)(shares)	7.83	7.82	7.26	6.75	6.75
Shares Outstanding (Diluted, Weighted)(shares)	7.83	7.82	7.26	6.75	6.75
EBITDA	0.85	3.88	3.09	2.49	2.98
Net Interest Income	–	–	0.18	0.18	-0.01

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2025

Gross margin: 29.2%
Operating margin: 2.9%
Net margin: 5.8%
Return on equity, FY2025: 4.1%

Financial strength

Current ratio: 1.95
Debt to equity: 0.69
Debt to assets: 37.3%
Cash to current liabilities: 39.8%

Valuation

P/E ratio: 10.5
Price to sales: –
Price to book: –
Dividend yield: –